Soft Tissue Sarcoma with Jonathan C. Trent, MD, PhD and Shreyaskumar R. Patel, MD: Case 1 - Episode 9
What is the risk:benefit of using ifosfamide in this patient?
Patients with metastatic or unresectable leiomyosarcoma are often treated with chemotherapy initially. That is usually an anthracycline-based regimen as frontline therapy. The anthracycline appears to be more active when used in combination.
In our practice, we use either ifosfamide or
, particularly in patients with uterine tumors. Patients with leiomyosarcoma arising outside of the uterus do not showcase exactly how ifosfamide adds to an anthracycline well enough.
CASE: Soft-Tissue Sarcoma (Part 1)
Rachel F is a 58-year-old school teacher from Roanoke, Virginia. Her medical history is notable for mild hypertension and total knee replacement in 2011
Follow-up CT scan in January 2014 showed progression at multiple sites; at the time of follow up, her ECOG performance status was 1, with renal and hepatic function within normal limits
In September of 2014 she returns for follow-up, unable to work with increasing fatigue and abdominal pain, and her CT scan was consistent with progressive disease
After 4 months of therapy, she presents with worsening abdominal pain and declining performance status